{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:02:45Z","timestamp":1783000965357,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jacasi.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:59:55Z","timestamp":1781240395000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Spironolactone and New-Onset Diabetes in Heart Failure"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7487-219X","authenticated-orcid":false,"given":"Dung Viet","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1742-3061","authenticated-orcid":false,"given":"Hoai Thi Thu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jacasi.2026.04.010_bib1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovi\u0107","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.jacasi.2026.04.010_bib2","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacasi.2026.04.010_bib3","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacasi.2026.04.010_bib4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2337\/dc08-1709","article-title":"Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program","volume":"32","author":"Preiss","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jacasi.2026.04.010_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-8587(24)00309-7","article-title":"Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial","volume":"13","author":"Butt","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"36","key":"10.1016\/j.jacasi.2026.04.010_bib6","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jacasi.2026.04.010_bib7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacasi.2026.04.010_bib8","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.jacasi.2026.04.010_bib9","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.04.010_bib10","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2025.28","article-title":"Cardiovascular benefits of spironolactone in heart failure with mildly reduced or preserved ejection fraction: insights from a win ratio analysis of the TOPCAT trial","volume":"11","author":"Nguyen","year":"2025","journal-title":"Card Fail Rev"},{"issue":"5","key":"10.1016\/j.jacasi.2026.04.010_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.pcad.2009.12.004","article-title":"Aldosterone: role in the cardiometabolic syndrome and resistant hypertension","volume":"52","author":"Whaley-Connell","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.jacasi.2026.04.010_bib12","doi-asserted-by":"crossref","first-page":"E110","DOI":"10.1152\/ajpendo.00258.2007","article-title":"Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat","volume":"295","author":"Lastra","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.jacasi.2026.04.010_bib13","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1(c) levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"},{"issue":"8","key":"10.1016\/j.jacasi.2026.04.010_bib14","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurjhf\/hfs067","article-title":"Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"14","author":"Preiss","year":"2012","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"10.1016\/j.jacasi.2026.04.010_bib15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacasi.2026.04.010_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacasi.2026.04.010_bib17","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction","volume":"162","author":"Desai","year":"2011","journal-title":"Am Heart J"},{"issue":"17","key":"10.1016\/j.jacasi.2026.04.010_bib18","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT - new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacasi.2026.04.010_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1536867X0400400201","article-title":"Cumulative incidence estimation in the presence of competing risks","volume":"4","author":"Coviello","year":"2004","journal-title":"Stata J"},{"issue":"6","key":"10.1016\/j.jacasi.2026.04.010_bib20","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/sim.2655","article-title":"Analysing and interpreting competing risk data","volume":"26","author":"Pintilie","year":"2007","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.jacasi.2026.04.010_bib21","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"issue":"446","key":"10.1016\/j.jacasi.2026.04.010_bib22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"10.1016\/j.jacasi.2026.04.010_bib23","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1177\/1536867X211063408","article-title":"Properly calculating estat phtest in the presence of stratified hazards","volume":"21","author":"Metzger","year":"2021","journal-title":"Stata J"},{"issue":"1s","key":"10.1016\/j.jacasi.2026.04.010_bib24","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.chest.2020.03.015","article-title":"A practical overview and reporting strategies for statistical analysis of survival studies","volume":"158","author":"Dey","year":"2020","journal-title":"Chest"},{"issue":"21","key":"10.1016\/j.jacasi.2026.04.010_bib25","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1002\/sim.1915","article-title":"Sample size formula for proportional hazards modelling of competing risks","volume":"23","author":"Latouche","year":"2004","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.jacasi.2026.04.010_bib26","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.amepre.2023.07.009","article-title":"Diabetes prevalence and incidence inequality trends among U.S. adults, 2008-2021","volume":"65","author":"Saelee","year":"2023","journal-title":"Am J Prev Med"},{"issue":"9","key":"10.1016\/j.jacasi.2026.04.010_bib27","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1210\/jc.2006-0736","article-title":"Insulin sensitivity in patients with primary aldosteronism: a follow-up study","volume":"91","author":"Catena","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.jacasi.2026.04.010_bib28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/1470320311402110","article-title":"Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease","volume":"12","author":"Polyzos","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"4","key":"10.1016\/j.jacasi.2026.04.010_bib29","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00125-010-2029-9","article-title":"Low serum potassium levels and risk of type 2 diabetes: the Toranomon Hospital Health Management Center Study 1 (TOPICS 1)","volume":"54","author":"Heianza","year":"2011","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.jacasi.2026.04.010_bib30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/jhh.2008.41","article-title":"Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial","volume":"22","author":"Aksnes","year":"2008","journal-title":"J Hum Hypertens"},{"issue":"2","key":"10.1016\/j.jacasi.2026.04.010_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacasi.2026.04.010_bib32","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/CIRCULATIONAHA.107.702795","article-title":"Metabolic mechanisms in heart failure","volume":"116","author":"Ashrafian","year":"2007","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacasi.2026.04.010_bib33","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1161\/CIRCRESAHA.116.306206","article-title":"Insulin signaling and heart failure","volume":"118","author":"Riehle","year":"2016","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.jacasi.2026.04.010_bib34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1586\/eem.11.60","article-title":"Potassium and risk of type 2 diabetes","volume":"6","author":"Chatterjee","year":"2011","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jacasi.2026.04.010_bib35","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1042\/cs1010739","article-title":"Cortisol increases gluconeogenesis in humans: its role in the metabolic syndrome","volume":"101","author":"Khani","year":"2001","journal-title":"Clin Sci (Lond)"},{"issue":"12","key":"10.1016\/j.jacasi.2026.04.010_bib36","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.metabol.2006.07.025","article-title":"The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy","volume":"55","author":"Matsumoto","year":"2006","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.jacasi.2026.04.010_bib37","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00125-004-1510-8","article-title":"Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes","volume":"47","author":"Davies","year":"2004","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.jacasi.2026.04.010_bib38","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00125-008-0972-5","article-title":"Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles","volume":"51","author":"Swaminathan","year":"2008","journal-title":"Diabetologia"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277237472600267X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277237472600267X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:00:01Z","timestamp":1781240401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277237472600267X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"alternative-id":["S277237472600267X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.04.010","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spironolactone and New-Onset Diabetes in Heart Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}